Medicare drug coverage

Copaxone: 2027 Medicare Part D coverage

1,124 of 5,495 Part D plans (20%) list Copaxone on their 2027 formulary, the plan's list of covered drugs (up 3 points from 2026). 100% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Copaxone is number 160 by total Medicare Part D spending in 2024 ($257 million). Plans that list it most often put it on tier 5 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 3 RxNorm products for this name.

Copaxone Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it922 (17%)1,124 (20%)+3 points
Prior authorization (of plans that list it)903 (98%)1,118 (99%)+1 point
Step therapy (of plans that list it)6 (1%)6 (1%)no change
Quantity limit (of plans that list it)848 (92%)1,124 (100%)+8 points
Any of the three (of plans that list it)922 (100%)1,124 (100%)no change
Not listed or restricted (of all plans)5,518 (100%)5,495 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

For pharmaciesFor agencies

Formulary tier

Copaxone formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 143 (5%)25 (2%)
Tier 43 (0%)0 (0%)
Tier 5876 (95%)1,099 (98%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 54 of them (1%) added prior authorization, step therapy, or a quantity limit for Copaxone, and 53 stopped listing it.

Copaxone: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 202753 (1%)
Listed it in 2027, not in 20267 (0%)
Moved it to a higher tier4 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit54 (1%)
Added at least one of the three54 (1%)
Removed at least one of the three0 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Copaxone off the formulary or list it with prior authorization, step therapy, or a quantity limit. All 51 states are at 100%. States at the same share are ordered by the prior authorization or step therapy share; states equal on both shares share a rank, marked Tied.

States from most to least restrictive for Copaxone, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Hawaii50100%48%no change
Tied 2Alabama115100%35%no change
Tied 2Maryland49100%35%no change
4Pennsylvania324100%34%no change
5Oregon92100%32%no change
6Arizona148100%31%no change
7Tennessee157100%29%no change
8New York215100%28%no change
9Connecticut54100%26%no change
Tied 10Illinois133100%24%no change
Tied 10New Hampshire25100%24%no change
Tied 12Indiana140100%23%no change
Tied 12Washington114100%23%no change
Tied 14Arkansas86100%21%no change
Tied 14Ohio173100%21%no change
Tied 16North Carolina177100%20%no change
Tied 16Colorado106100%20%no change
Tied 16Nebraska51100%20%no change
Tied 19California397100%19%no change
Tied 19Florida549100%19%no change
Tied 19Mississippi105100%19%no change
Tied 19Delaware43100%19%no change
Tied 23Louisiana126100%18%no change
Tied 23Missouri171100%18%no change
Tied 23New Mexico68100%18%no change
26Iowa64100%17%no change
27Texas412100%16%no change
Tied 28Maine52100%15%no change
Tied 28Massachusetts92100%15%no change
Tied 28Utah53100%15%no change
Tied 28Oklahoma81100%15%no change
Tied 28Michigan183100%15%no change
Tied 33Vermont14100%14%no change
Tied 33Rhode Island29100%14%no change
35Kansas84100%13%no change
36Virginia145100%12%no change
Tied 37West Virginia70100%11%no change
Tied 37South Carolina91100%11%no change
Tied 37Georgia151100%11%no change
Tied 37Kentucky123100%11%no change
41New Jersey74100%8%no change
42Idaho45100%7%no change
43District of Columbia21100%5%no change
Tied 44Wisconsin97100%4%no change
Tied 44Nevada100100%4%no change
46Minnesota63100%2%no change
Tied 47Alaska9100%0%no change
Tied 47Montana27100%0%no change
Tied 47North Dakota26100%0%no change
Tied 47South Dakota30100%0%no change
Tied 47Wyoming13100%0%no change

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Copaxone off or restrict it.

Copaxone coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
BrightSpring Health Services, Inc.20%none list it100%no change0
Community Health Group20%none list it100%no change0
Community Health Plan of Washington20%none list it100%no change0
Denver Health and Hospital Authority20%none list it100%no change0
Elevance Health, Inc. & BCBSMA & BCBSRI & BCBSVT2100%100%100%no change0
Elite Health Systems, Inc.20%none list it100%no change0
Group Health Cooperative of Eau Claire20%none list it100%no change0
Hamaspik of Rockland County, Inc.20%none list it100%no change0
ISNP Holdings, LLC20%none list it100%no change0
Kansas Superior Select20%none list it100%no change0
Missouri Healthcare Advisors, LLC20%none list it100%no change0
MultiCare Health Systems20%none list it100%new in 20270
NEIGHBORHOOD HEALTH PLAN OF RHODE ISLAND2100%100%100%no change0
PrimeWest Rural MN Health Care Access Initiative20%none list it100%no change0
Regency ISNP Holdings LLC20%none list it100%no change0
Select Founders, LLC20%none list it100%no change0
Sentara Health Care (SHC)20%none list it100%no change0
South Country Health Alliance20%none list it100%no change0
The Regents of the University of California20%none list it100%no change0
Troy Holdings, Inc.20%none list it100%no change0
Associated Care Ventures, Inc.30%none list it100%no change0
Aultman Health Foundation30%none list it100%no change0
Banner Health30%none list it100%no change0
Bexar County Hospital District30%none list it100%no change0
Blue Cross Blue Shield of Nebraska30%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing